The clinical development of new mitotic inhibitors that stabilize the microtubule

Sridhar Mani, Manuel Macapinlac, Sanjay Goel, Dominik Verdier-Pinard, Tito Fojo, Mace Rothenberg, Dimitrios Colevas

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Microtubule-stabilizing agents are increasingly studied for cancer treatment based largely on the prior success of paclitaxel and docetaxel. In this review, we focus on the clinical development of epothilones and discodermolide, and we discuss salient preclinical and clinical highlights of these two novel natural products. These agents are distinguished by their biochemical features making them poor P-glycoprotein substrates and capable of inducing cytotoxicity in cell lines or in vivo tumor models harboring mutations in tubulin. There is now considerable data regarding the efficacy of the epothilones in human beings and discodermolide holds such promise, as well.

Original languageEnglish (US)
Pages (from-to)553-558
Number of pages6
JournalAnti-Cancer Drugs
Volume15
Issue number6
DOIs
StatePublished - Jul 2004

Fingerprint

Epothilones
docetaxel
Microtubules
Excipients
P-Glycoprotein
Tubulin
Paclitaxel
Biological Products
Neoplasms
Cell Line
Mutation
discodermolide
Therapeutics

Keywords

  • Discodermolide
  • Eluethrobin
  • Epothilones
  • Microtubule binding drugs
  • Taxanes

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

The clinical development of new mitotic inhibitors that stabilize the microtubule. / Mani, Sridhar; Macapinlac, Manuel; Goel, Sanjay; Verdier-Pinard, Dominik; Fojo, Tito; Rothenberg, Mace; Colevas, Dimitrios.

In: Anti-Cancer Drugs, Vol. 15, No. 6, 07.2004, p. 553-558.

Research output: Contribution to journalArticle

Mani, S, Macapinlac, M, Goel, S, Verdier-Pinard, D, Fojo, T, Rothenberg, M & Colevas, D 2004, 'The clinical development of new mitotic inhibitors that stabilize the microtubule', Anti-Cancer Drugs, vol. 15, no. 6, pp. 553-558. https://doi.org/10.1097/01.cad.0000131681.21637.b2
Mani, Sridhar ; Macapinlac, Manuel ; Goel, Sanjay ; Verdier-Pinard, Dominik ; Fojo, Tito ; Rothenberg, Mace ; Colevas, Dimitrios. / The clinical development of new mitotic inhibitors that stabilize the microtubule. In: Anti-Cancer Drugs. 2004 ; Vol. 15, No. 6. pp. 553-558.
@article{261e6071b3be4fb38f6ade0cc6e1cbd6,
title = "The clinical development of new mitotic inhibitors that stabilize the microtubule",
abstract = "Microtubule-stabilizing agents are increasingly studied for cancer treatment based largely on the prior success of paclitaxel and docetaxel. In this review, we focus on the clinical development of epothilones and discodermolide, and we discuss salient preclinical and clinical highlights of these two novel natural products. These agents are distinguished by their biochemical features making them poor P-glycoprotein substrates and capable of inducing cytotoxicity in cell lines or in vivo tumor models harboring mutations in tubulin. There is now considerable data regarding the efficacy of the epothilones in human beings and discodermolide holds such promise, as well.",
keywords = "Discodermolide, Eluethrobin, Epothilones, Microtubule binding drugs, Taxanes",
author = "Sridhar Mani and Manuel Macapinlac and Sanjay Goel and Dominik Verdier-Pinard and Tito Fojo and Mace Rothenberg and Dimitrios Colevas",
year = "2004",
month = "7",
doi = "10.1097/01.cad.0000131681.21637.b2",
language = "English (US)",
volume = "15",
pages = "553--558",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The clinical development of new mitotic inhibitors that stabilize the microtubule

AU - Mani, Sridhar

AU - Macapinlac, Manuel

AU - Goel, Sanjay

AU - Verdier-Pinard, Dominik

AU - Fojo, Tito

AU - Rothenberg, Mace

AU - Colevas, Dimitrios

PY - 2004/7

Y1 - 2004/7

N2 - Microtubule-stabilizing agents are increasingly studied for cancer treatment based largely on the prior success of paclitaxel and docetaxel. In this review, we focus on the clinical development of epothilones and discodermolide, and we discuss salient preclinical and clinical highlights of these two novel natural products. These agents are distinguished by their biochemical features making them poor P-glycoprotein substrates and capable of inducing cytotoxicity in cell lines or in vivo tumor models harboring mutations in tubulin. There is now considerable data regarding the efficacy of the epothilones in human beings and discodermolide holds such promise, as well.

AB - Microtubule-stabilizing agents are increasingly studied for cancer treatment based largely on the prior success of paclitaxel and docetaxel. In this review, we focus on the clinical development of epothilones and discodermolide, and we discuss salient preclinical and clinical highlights of these two novel natural products. These agents are distinguished by their biochemical features making them poor P-glycoprotein substrates and capable of inducing cytotoxicity in cell lines or in vivo tumor models harboring mutations in tubulin. There is now considerable data regarding the efficacy of the epothilones in human beings and discodermolide holds such promise, as well.

KW - Discodermolide

KW - Eluethrobin

KW - Epothilones

KW - Microtubule binding drugs

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=3142704182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142704182&partnerID=8YFLogxK

U2 - 10.1097/01.cad.0000131681.21637.b2

DO - 10.1097/01.cad.0000131681.21637.b2

M3 - Article

C2 - 15205596

AN - SCOPUS:3142704182

VL - 15

SP - 553

EP - 558

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 6

ER -